Literature DB >> 32512858

The miR-26b-5p/KPNA2 Axis Is an Important Regulator of Burkitt Lymphoma Cell Growth.

Fubiao Niu1, Marta Kazimierska2, Ilja M Nolte3, Miente Martijn Terpstra4, Debora de Jong1, Jasper Koerts1, Tineke van der Sluis1, Bea Rutgers1, Ryan M O'Connell5, Klaas Kok4, Anke van den Berg1, Agnieszka Dzikiewicz-Krawczyk2, Joost Kluiver1.   

Abstract

The expression of several microRNAs (miRNAs) is known to be changed in Burkitt lymphoma (BL), compared to its normal counterparts. Although for some miRNAs, a role in BL was demonstrated, for most of them, their function is unclear. In this study, we aimed to identify miRNAs that control BL cell growth. Two BL cell lines were infected with lentiviral pools containing either 58 miRNA inhibitors or 44 miRNA overexpression constructs. Eighteen constructs showed significant changes in abundance over time, indicating that they affected BL growth. The screening results were validated by individual green fluorescent protein (GFP) growth competition assays for fifteen of the eighteen constructs. For functional follow-up studies, we focused on miR-26b-5p, whose overexpression inhibited BL cell growth. Argonaute 2 RNA immunoprecipitation (Ago2-IP) in two BL cell lines revealed 47 potential target genes of miR-26b-5p. Overlapping the list of putative targets with genes showing a growth repression phenotype in a genome-wide CRISPR/Cas9 knockout screen, revealed eight genes. The top-5 candidates included EZH2, COPS2, KPNA2, MRPL15, and NOL12. EZH2 is a known target of miR-26b-5p, with oncogenic properties in BL. The relevance of the latter four targets was confirmed using sgRNAs targeting these genes in individual GFP growth competition assays. Luciferase reporter assay confirmed binding of miR-26b-5p to the predicted target site for KPNA2, but not to the other genes. In summary, we identified 18 miRNAs that affected BL cell growth in a loss- or gain-of-function screening. A tumor suppressor role was confirmed for miR-26b-5p, and this effect could at least in part be attributed to KPNA2, a known regulator of OCT4, c-jun, and MYC.

Entities:  

Keywords:  Burkitt lymphoma; KPNA2; miR-26b-5p; microRNA

Year:  2020        PMID: 32512858     DOI: 10.3390/cancers12061464

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  7 in total

1.  Prognostic Value and Related Regulatory Networks of MRPL15 in Non-Small-Cell Lung Cancer.

Authors:  Yangyang Zeng; Yingying Shi; Lu Xu; Yulan Zeng; Xiao Cui; Yuan Wang; Ningning Yang; Fuxiang Zhou; Yunfeng Zhou
Journal:  Front Oncol       Date:  2021-05-07       Impact factor: 6.244

2.  The Role of the MYC/miR-150/MYB/ZDHHC11 Network in Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma.

Authors:  Lotteke J Y M Ziel-Swier; Yichen Liu; Annika Seitz; Debora de Jong; Jasper Koerts; Bea Rutgers; Rianne Veenstra; Fazlyn R Abdul Razak; Agnieszka Dzikiewicz-Krawczyk; Anke van den Berg; Joost Kluiver
Journal:  Genes (Basel)       Date:  2022-01-25       Impact factor: 4.096

3.  Circular RNA_ANKIB1 accelerates chemo-resistance of osteosarcoma via binding microRNA-26b-5p and modulating enhancer of zeste homolog 2.

Authors:  JinShan Tang; Gang Duan; YunQing Wang; Bin Wang; WenBo Li; ZiQiang Zhu
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

4.  MicroRNA-26b-5p suppresses the proliferation of tongue squamous cell carcinoma via targeting proline rich 11 (PRR11).

Authors:  Liang Yi; Ying Liu; Anji Xu; Sha Li; Hailin Zhang; Mingjing Peng; Zan Li; Huayi Ren; Jie Dai; Chenhui Luo; Yazhou Xiao; Xiao Zhou; Ying Long
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  Long non-coding RNA HAGLROS facilitates tumorigenesis and progression in hepatocellular carcinoma by sponging miR-26b-5p to up-regulate karyopherin α2 (KPNA2) and inactivate p53 signaling.

Authors:  Gaofeng Tang; Huibo Zhao; Zhantao Xie; Sidong Wei; Guoyong Chen
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

6.  Prognostic Values From Integrated Analysis of the Nomogram Based on RNA-Binding Proteins and Clinical Factors in Endometrial Cancer.

Authors:  Shuang Yuan; Xiao Sun; Lihua Wang
Journal:  Clin Med Insights Oncol       Date:  2022-09-28

7.  Advances and Perspectives in the Treatment of B-Cell Malignancies.

Authors:  Marta Cuenca; Victor Peperzak
Journal:  Cancers (Basel)       Date:  2021-05-08       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.